Summary

Middle East and Africa blood plasma & plasma derived medicinal Products market is expected to reach USD 2.16 billion by 2032 from USD 1.34 billion in 2024, growing at a CAGR of 6.25% during the forecast period of 2025 to 2032.

Market Segmentation:
Middle East and Africa Blood Plasma & Plasma Derived Medicinal Products Market, By Product (Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins), Application (Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications), Processing Technology (Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration), Mode (Modern and Traditional Plasma Fractionation), End-User (Hospitals & Clinics, Research Labs, Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Poland, Denmark, Sweden, Belgium, Ireland, Norway, Finland, Rest of Europe, China, Japan, South Korea, Australia, India, Malaysia, Thailand, Singapore, Philippines, Indonesia, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Columbia, Chile, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Bahrain, Kuwait, Oman, Qatar, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032
Overview of the Middle East and Africa Blood Plasma & Plasma Derived Medicinal Market Dynamics:
Drivers
• Rising prevalence of rare and chronic diseases
• Expanding geriatric population
Restraints
• High cost and complex manufacturing process
• Lack of plasma supply and donor
Opportunities
• Advancements in plasma processing technologies to enhance yield and reduce costs
• Reimbursement frameworks and increased governmental focus on rare disease treatment
Market Players:
The key players operating in the Middle East and Africa blood plasma & plasma derived medicinal products market are:
• CSL
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma AG
• Kedrion
• Biotest AG
• Fresenius Kabi AG
• Kamada Pharmaceuticals
• KM Biologics
• Reliance Life Sciences
• SK Plasma
• Synthaverse S. A.
• VIRCHOW BIOTECH

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 89
1.1 OBJECTIVES OF THE STUDY 89
1.2 MARKET DEFINITION 89
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 89
1.4 LIMITATIONS 91
1.5 MARKETS COVERED 92
2 MARKET SEGMENTATION 95
2.1 MARKETS COVERED 95
2.2 GEOGRAPHICAL SCOPE 96
2.3 YEARS CONSIDERED FOR THE STUDY 97
2.4 CURRENCY AND PRICING 97
2.5 DBMR TRIPOD DATA VALIDATION MODEL 98
2.6 MULTIVARIATE MODELLING 101
2.7 PRODUCT LIFELINE CURVE 101
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 102
2.9 DBMR MARKET POSITION GRID 103
2.10 MARKET END USER COVERAGE GRID 104
2.11 VENDOR SHARE ANALYSIS 105
2.12 SECONDARY SOURCES 106
2.13 ASSUMPTIONS 106
3 EXECUTIVE SUMMARY 107
4 PREMIUM INSIGHTS 112
4.1 PESTLE ANALYSIS 113
4.1.1 POLITICAL FACTORS 113
4.1.2 ECONOMIC FACTORS 113
4.1.3 SOCIAL FACTORS 113
4.1.4 TECHNOLOGICAL FACTORS 114
4.1.5 ENVIRONMENTAL FACTORS 114
4.1.6 LEGAL FACTORS 114
4.2 PORTER’S FIVE FORCES 115
4.2.1 THREAT OF NEW ENTRANTS 115
4.2.2 BARGAINING POWER OF SUPPLIERS 115
4.2.3 BARGAINING POWER OF BUYERS 116
4.2.4 THREAT OF SUBSTITUTES 116
4.2.5 INDUSTRY RIVALRY 116
4.3 SUPPLY CHAIN IMPACT ON THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET 117
4.3.1 OVERVIEW 117
4.3.2 RAW MATERIAL AVAILABILITY 117
4.3.3 MANUFACTURING CAPACITY 117
4.3.4 LOGISTICS AND LAST-MILE HURDLES 117
4.3.5 PRICING MODELS AND MARKET POSITIONING 118
4.4 INNOVATION STRATEGIES 119
4.4.1 KEY INNOVATION STRATEGIES 119
4.4.2 EMERGING DELIVERY TECHNIQUES 120
4.4.3 STRATEGIC IMPLICATIONS 120
4.4.4 CONCLUSION 120
4.5 RISK AND MITIGATION 121
4.6 VENDOR SELECTION DYNAMICS 123
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE 123
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY 123
4.6.3 CLINICAL EFFICACY AND INNOVATION 123
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY 123
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE 123
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY 124
4.6.7 CONCLUSION 124
4.7 TARIFFS AND THEIR IMPACT ON MARKET 125
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS 125
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE 125
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS 125
4.7.4 IMPACT ON SUPPLY CHAIN 126
4.7.5 IMPACT ON PRICES 126
4.7.6 REGULATORY INCLINATION 126
4.7.6.1 GCC TRADE ALIGNMENT & FTAS 126
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS 126
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE 126
4.7.6.4 DOMESTIC COURSE OF CORRECTION 126
5 REGULATION COVERAGE 128
6 MARKET OVERVIEW 131
6.1 DRIVERS 133
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES 133
6.1.2 EXPANDING GERIATRIC POPULATION 133
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION 134
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT 135
6.2 RESTRAINTS 136
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS 136
6.2.2 LACK OF PLASMA SUPPLY AND DONOR 136
6.3 OPPORTUNITIES 137
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS 137
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT 138
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN MIDDLE EAST AND AFRICA MARKET PENETRATION 139
6.4 CHALLENGES 140
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES 140
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION 140
7 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT 142
7.1 OVERVIEW 143
7.2 IMMUNOGLOBULINS 146
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS) 148
7.4 ALBUMIN (PLASMA VOLUME EXPANDER) 153
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) 154
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) 156
7.7 OTHER PLASMA DERIVED PROTEINS 157
8 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION 159
8.1 OVERVIEW 160
8.2 IMMUNOLOGY 163
8.3 HEMATOLOGY 163
8.4 CRITICAL CARE 164
8.5 NEUROLOGY 164
8.6 PULMONOLOGY 165
8.7 HAEMATO-ONCOLOGY 165
8.8 RHEUMATOLOGY 166
8.9 OTHER APPLICATIONS 166
9 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY 167
9.1 OVERVIEW 168
9.2 ION EXCHANGE CHROMATOGRAPHY 171
9.3 AFFINITY CHROMATOGRAPHY 171
9.4 CRYOPRECIPITATION 172
9.5 ULTRAFILTRATION 172
9.6 MICROFILTRATION 173
10 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE 174
10.1 OVERVIEW 175
10.2 MODERN 178
10.3 TRADITIONAL PLASMA FRACTIONATION 178
11 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER 179
11.1 OVERVIEW 180
11.2 HOSPITALS & CLINICS 183
11.3 RESEARCH LABS 183
11.4 ACADEMIC INSTITUTES 184
11.5 OTHERS 184
12 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 185
12.1 OVERVIEW 186
12.2 DIRECT TENDERS 189
12.3 THIRD PARTY DISTRIBUTORS 189
12.4 OTHERS 190
13 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION 191
13.1 MIDDLE EAST AND AFRICA 193
13.1.1 SOUTH AFRICA 203
13.1.2 SAUDI ARABIA 212
13.1.3 U.A.E. 221
13.1.4 ISRAEL 230
13.1.5 EGYPT 239
13.1.6 BAHRAIN 247
13.1.7 KUWAIT 256
13.1.8 OMAN 264
13.1.9 QATAR 272
13.1.10 REST OF MIDDLE EAST AND AFRICA 280
14 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE 281
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 281
15 SWOT ANALYSIS 282
16 COMPANY PROFILE 283
16.1 CSL 283
16.1.1 COMPANY SNAPSHOT 283
16.1.2 REVENUE ANALYSIS 283
16.1.3 COMPANY SHARE ANALYSIS 284
16.1.4 PRODUCT PORTFOLIO 284
16.1.5 RECENT DEVELOPMENTS 285
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 286
16.2.1 COMPANY SNAPSHOT 286
16.2.2 REVENUE ANALYSIS 287
16.2.3 COMPANY SHARE ANALYSIS 287
16.2.4 PRODUCT PORTFOLIO 288
16.2.5 RECENT DEVELOPMENTS 288
16.3 GRIFOLS, S.A. 289
16.3.1 COMPANY SNAPSHOT 289
16.3.2 REVENUE ANALYSIS 289
16.3.3 COMPANY SHARE ANALYSIS 290
16.3.4 PRODUCT PORTFOLIO 290
16.3.5 RECENT DEVELOPMENTS 292
16.4 OCTAPHARMA AG 293
16.4.1 COMPANY SNAPSHOT 293
16.4.2 COMPANY SHARE ANALYSIS 293
16.4.3 PRODUCT PORTFOLIO 294
16.4.4 RECENT DEVELOPMENTS 296
16.5 KEDRION 297
16.5.1 COMPANY SNAPSHOT 297
16.5.2 COMPANY SHARE ANALYSIS 297
16.5.3 PRODUCT PORTFOLIO 298
16.5.4 RECENT DEVELOPMENT 298
16.6 ADMA BIOLOGICS, INC 299
16.6.1 COMPANY SNAPSHOT 299
16.6.2 REVENUE ANALYSIS 299
16.6.3 PRODUCT PORTFOLIO 300
16.6.4 RECENT DEVELOPMENT 300
16.7 AEGROS 301
16.7.1 COMPANY SNAPSHOT 301
16.7.2 PRODUCT PORTFOLIO 301
16.7.3 RECENT DEVELOPMENT 301
16.8 BHARAT SERUMS 302
16.8.1 COMPANY SNAPSHOT 302
16.8.2 PRODUCT PORTFOLIO 302
16.8.3 RECENT DEVELOPMENT 302
16.9 BIOTEST AG. 303
16.9.1 COMPANY SNAPSHOT 303
16.9.2 REVENUE ANALYSIS 303
16.9.3 PRODUCT PORTFOLIO 304
16.9.4 RECENT DEVELOPMENTS 306
16.10 FRESENIUS KABI AG 307
16.10.1 COMPANY SNAPSHOT 307
16.10.2 PRODUCT PORTFOLIO 307
16.10.3 RECENT DEVELOPMENT 307
16.11 GC BIOPHARMA CORPORATE 308
16.11.1 COMPANY SNAPSHOT 308
16.11.2 REVENUE ANALYSIS 308
16.11.3 PRODUCT PORTFOLIO 309
16.11.4 RECENT DEVELOPMENT 310
16.12 ICHOR 311
16.12.1 COMPANY SNAPSHOT 311
16.12.2 PRODUCT PORTFOLIO 311
16.12.3 RECENT DEVELOPMENT 315
16.13 INTAS PHARMACEUTICALS LTD. 316
16.13.1 COMPANY SNAPSHOT 316
16.13.2 PRODUCT PORTFOLIO 316
16.13.3 RECENT DEVELOPMENT 316
16.14 KAMADA PHARMACEUTICALS 317
16.14.1 COMPANY SNAPSHOT 317
16.14.2 REVENUE ANALYSIS 317
16.14.3 PRODUCT PORTFOLIO 318
16.14.4 RECENT DEVELOPMENT 319
16.15 KM BIOLOGICS 320
16.15.1 COMPANY SNAPSHOT 320
16.15.2 PRODUCT PORTFOLIO 320
16.15.3 RECENT DEVELOPMENT 320
16.16 LFB 321
16.16.1 COMPANY SNAPSHOT 321
16.16.2 PRODUCT PORTFOLIO 321
16.16.3 RECENT DEVELOPMENT 323
16.17 PLASMAGEN BIOSCIENCES PVT. LTD. 324
16.17.1 COMPANY SNAPSHOT 324
16.17.2 PRODUCT PORTFOLIO 324
16.17.3 RECENT DEVELOPMENTS 326
16.18 PROLIANT HEALTH & BIOLOGICALS 327
16.18.1 COMPANY SNAPSHOT 327
16.18.2 PRODUCT PORTFOLIO 327
16.18.3 RECENT DEVELOPMENT 327
16.19 PROMEA 328
16.19.1 COMPANY SNAPSHOT 328
16.19.2 PRODUCT PORTFOLIO 328
16.19.3 RECENT DEVELOPMENT 329
16.20 RELIANCE LIFE SCIENCES 330
16.20.1 COMPANY SNAPSHOT 330
16.20.2 BUSINESS PORTFOLIO 330
16.20.3 RECENT DEVELOPMENT 331
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD. 332
16.21.1 COMPANY SNAPSHOT 332
16.21.2 PRODUCT PORTFOLIO 332
16.21.3 RECENT DEVELOPMENT 333
16.22 SK PLASMA 334
16.22.1 COMPANY SNAPSHOT 334
16.22.2 PRODUCT PORTFOLIO 334
16.22.3 RECENT DEVELOPMENT 335
16.23 SYNTHAVERSE S. A. 336
16.23.1 COMPANY SNAPSHOT 336
16.23.2 REVENUE ANALYSIS 337
16.23.3 PRODUCT PORTFOLIO 337
16.23.4 RECENT DEVELOPMENTS 338
16.24 TAIBANG BIO GROUP CO., LTD 339
16.24.1 COMPANY SNAPSHOT 339
16.24.2 PRODUCT PORTFOLIO 339
16.24.3 RECENT DEVELOPMENT 339
16.25 VIRCHOW BIOTECH 340
16.25.1 COMPANY SNAPSHOT 340
16.25.2 PRODUCT PORTFOLIO 340
16.25.3 RECENT DEVELOPMENT 342
17 QUESTIONNAIRE 343
18 RELATED REPORTS 346